Janus Henderson Group PLC grew its holdings in Insulet Co. (NASDAQ:PODD – Free Report) by 14.6% during the third quarter, ...

Right now, ResMed is sporting a Zacks Rank of #2 (Buy), while Insulet has a Zacks Rank of #3 (Hold). This means that RMD's earnings estimate revision activity has been more impressive, so investors ...

Insulet Corp., manufacturer of the tubeless Omnipod Insulin Management System, has been awarded $452 million in damages after it successfully defended its intellectual property against ...

With 27 witnesses, plus both patent infringement and misappropriation claims, lead counsel for Insulet Alexandra Valenti and ...

In a report released yesterday, Robbie Marcus from J.P. Morgan maintained a Buy rating on Insulet (PODD – Research Report), with a price target ...

Analyst Patrick Wood from Morgan Stanley maintained a Buy rating on Insulet (PODD – Research Report) and keeping the price target at ...

A Cornerstone in Diabetes ManagementInsulin delivery devices market are innovative medical instruments designed to provide ...

11 analysts have shared their evaluations of Insulet PODD during the recent three months, expressing a mix of bullish and ...

Citi Research analysts updated their “SMID value creators” list, removing Globant . The “SMID Value Creators List” names buy-rated stocks by Citi analysts ...

Google broke out on its Willow quantum computing chip as Tesla races. But that masked underlying weakness in growth stocks ...

In this video, Joseph Hog discusses growth stocks that offer potential for triple-digit returns without the risk of ...

AFib-treating cardiac ablation, surgical robotics, nitinol and diabetes treatment tech lead among this year’s top medtech ...